SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS WITH INADEQUATE RESPONSE TO TNF INHIBITORS

被引：1
|
作者：
Fleischmann, R. [1 ]
Hrycaj, P. [2 ]
van Hoogstraten, H. [3 ]
Mangan, E. K. [4 ]
Lin, Y. [3 ]
Jayawardena, S. [3 ]
Burmester, G. R. [5 ,6 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Metroplex Clin Res Ctr, Dallas, TX 75390 USA
[2] Poznan Univ Med Sci, Dept Rheumatol & Clin Immunol, Poznan, Poland
[3] Sanofi Genzyme, Bridgewater, MA USA
[4] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[5] Free Univ, Charite Univ Med Berlin, Berlin, Germany
[6] Humboldt Univ, Berlin, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.5155
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0212
引用
收藏
页码：853 / 853
页数：1
相关论文
共 50 条
  • [21] Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study
    Strand, Vibeke
    Reaney, Matthew
    Mangan, Erin
    van Hoogstraten, Hubert
    Boklage, Susan
    Hu, Chih-Chi
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [22] Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors.
    Kremer, J. M.
    Tony, H. P.
    Tak, P. P.
    Luggen, M.
    Mariette, X.
    Hessey, E.
    McCabe, D.
    Safa-Leathers, S.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S247 - S248
  • [23] Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice
    Vivian P. Bykerk
    Andrew J. K. Östör
    José Alvaro-Gracia
    Karel Pavelka
    José Andrés Román Ivorra
    Michael T. Nurmohamed
    Yves Luder
    Paris N. M. Sidiropoulos
    Jenny Devenport
    Jean Sibilia
    Clinical Rheumatology, 2019, 38 : 2411 - 2421
  • [24] Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice
    Bykerk, Vivian P.
    Ostor, Andrew J. K.
    Alvaro-Gracia, Jose
    Pavelka, Karel
    Roman Ivorra, Jose Andres
    Nurmohamed, Michael T.
    Luder, Yves
    Sidiropoulos, Paris N. M.
    Devenport, Jenny
    Sibilia, Jean
    CLINICAL RHEUMATOLOGY, 2019, 38 (09) : 2411 - 2421
  • [25] Interim analysis: Open-label extension study of leniolisib for patients with APDS
    Rao, V. Koneti
    Kulm, Elaine
    Sediva, Anna
    Plebani, Alessandro
    Schuetz, Catharina
    Shcherbina, Anna
    Dalm, Virgil A.
    Trizzino, Antonino
    Zharankova, Yulia
    Webster, Sharon
    Orpia, Alanvin
    Koeurorholz, Julia
    Lougaris, Vassilios
    Rodina, Yulia
    Radford, Kath
    Bradt, Jason
    Relan, Anurag
    Holland, Steven M.
    Lenardo, Michael J.
    Uzel, Gulbu
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (01) : 265 - 274.e9
  • [26] Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
    Perez de Llano, Luis A.
    Cosio, Borja G.
    Domingo, Christian
    Urrutia, Isabel
    Bobolea, Irina
    Valero, Antonio
    Entrenas Costa, Luis M.
    Quirce, Santiago
    Barranco, Pilar
    Marina Malanda, Nuria
    Prieto Andres, Luis
    Alvarez-Gutierrez, Francisco J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2019, 7 (07): : 2277 - +
  • [27] PATIENTS (PTS) SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN RA DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION (OLE)
    Burmester, Gerd Ruediger
    Amital, Howard
    Rubbert-Roth, Andrea
    van Hoogstraten, Hubert
    Gervitz, Leonm.
    Thangavelu, Karthinathan
    St John, Gregory
    Genovese, Mark C.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1138 - 1139
  • [28] An Open-label Dose-response Study of Losartan in Hypertensive Children
    Webb, Nicholas J. A.
    Wells, Thomas G.
    Shahinfar, Shahnaz
    Massaad, Rachid
    Dankner, Wayne M.
    Lam, Chun
    Santoro, Emanuela P.
    Sisk, Christine McCrary
    Blaunstein, Robert O.
    PEDIATRIC NEPHROLOGY, 2013, 28 (08) : 1636 - 1636
  • [29] A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
    Howard, Jo
    Hemmaway, Claire Jane
    Telfer, Paul
    Layton, D. Mark
    Porter, John
    Awogbade, Moji
    Mant, Timothy
    Gretler, Daniel D.
    Dufu, Kobina
    Hutchaleelaha, Athiwat
    Patel, Mira
    Siu, Vincent
    Dixon, Sandra
    Landsman, Noel
    Tonda, Margaret
    Lehrer-Graiwer, Joshua
    BLOOD, 2019, 133 (17) : 1865 - 1875
  • [30] A SIX-MONTH OPEN-LABEL EXTENSION STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS
    Findling, Robert L.
    Robb, Adelaide S.
    DelBello, Melissa P.
    Huss, Michael
    McNamara, Nora K.
    Sarkis, Elias H.
    Scheffer, Russell E.
    Poulsen, Lis H.
    Chen, Grace
    Lemming, Ole M.
    Auby, Philippe
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2016, 55 (10): : S183 - S183
12345